Blueprint Medicines Corp (NASDAQ:BPMC) reported a challenging fourth quarter for 2024, missing analyst expectations for both earnings per share (EPS) and revenue. The company posted an EPS of -0.79, ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.